QUANTA-CLOUD-TECHNOLOGY
24.5.2022 06:02:09 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced new servers that will support the NVIDIA Grace™ CPU Superchip and Grace™ Hopper™ Superchip . QCT is incorporating the NVIDIA Grace™ CPU, striving for the highest performance, memory bandwidth, energy efficiency and configurability that is ready for the modern data center and addresses the most demanding artificial intelligence (AI), high-performance computing (HPC), data analytics, digital twins, cloud gaming, and hyperscale computing applications.
Breakthrough CPU for the Modern Data Center
The NVIDIA Grace CPU Superchip is a breakthrough processor designed for the modern data center, providing the highest performance and twice the memory bandwidth and energy-efficiency compared to today’s leading server processors. The NVIDIA Grace CPU Superchip can be used standalone or with NVIDIA’s industry-leading GPU and BlueField® data processing unit (DPU) building blocks. The Grace Hopper Superchip pairs an NVIDIA Grace CPU with an NVIDIA Hopper architecture-based GPU. The integrated module is designed to serve HPC and giant-scale AI applications. The NVIDIA Grace Hopper Superchip will enable up to 10x higher performance in a variety of configurations for applications running terabytes of data, enabling scientists and researchers to reach unprecedented solutions to the world’s most complex problems.
“As a leading cloud enabler, QCT is committed to being a critical enabler for AI and HPC applications for the modern data center,” said Mike Yang, President of QCT. “We are thrilled to broaden our compute portfolio with the NVIDIA Grace CPU Superchip and Grace Hopper Superchip. As we are seeing a rise in the multitude of AI applications, QCT works closely with NVIDIA to ensure our clients can benefit from the latest and greatest CPU, GPU and networking technologies.”
QCT will add the new NVIDIA Grace CPU Superchip and Grace Hopper Superchip to its extensive server portfolio to deliver unprecedented accelerated computing. Designed to interface with the latest PCIe Gen5 protocol, this will be the fastest communication to enable optimal connectivity with the highest-performing GPUs, and the fastest networking with up to 400 gigabits per second (Gb/s) Ethernet or NVIDIA Quantum-2 400Gb/s InfiniBand with NVIDIA ConnectX®-7 smart network interface cards (SmartNICs) and BlueField-3 DPUs to provide best-in-class acceleration for secure HPC and AI workloads. These new QCT server systems will be released next year and will also support NVIDIA’s computing software stacks, including NVIDIA HPC, NVIDIA AI, Omniverse and NVIDIA RTX.
Follow QCT on Facebook and Twitter to receive the latest news and announcements.
About QCT
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.qct.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom